Get started
Author

Teruo Jojima

Observed names: Jojima, Teruo, T. Jojima, TERUO JOJIMA
ORCID: 0000-0002-2907-261X
Observed ORCID: 0000-0002-2907-261X
OpenAlex ID: A5066098744
Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease
2018 · Masanori Shimizu, Kunihiro Suzuki, et al. · Diabetes Obesity and Metabolism · 409
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
2016 · Teruo Jojima, Takanori Tomotsune, et al. · Diabetology & Metabolic Syndrome · 206
PDF
RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
2010 · Y. Hattori, T. Jojima, et al. · Diabetologia · 186
PDF
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
2019 · Teruo Jojima, Sho Wakamatsu, et al. · International Journal of Molecular Sciences · 126
PDF
Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice
2017 · Teruo Jojima, Kohsuke Uchida, et al. · Atherosclerosis · 109
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease
2019 · Yoshimasa Aso, Kanako Kato, et al. · International Journal of Clinical Practice · 100
PDF
Aldosterone Impairs Vascular Endothelial Cell Function
2006 · Yuko Hashikabe, Kunihiro Suzuki, et al. · Journal of Cardiovascular Pharmacology · 94
Impact of sex, fat distribution and initial body weight on oxytocin’s body weight regulation
2017 · Yuko Maejima, Masato Aoyama, et al. · Scientific Reports · 61
PDF
Anti-Inflammatory Role of Cilostazol in Vascular Smooth Muscle Cells In vitro and In vivo
2010 · Chie Aoki, Yoshiyuki Hattori, et al. · Journal of Atherosclerosis and Thrombosis · 53
PDF
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes
2015 · Yoshimasa Aso, Maiko Fukushima, et al. · Diabetes Research and Clinical Practice · 42
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
2020 · Shintaro Sakurai, Teruo Jojima, et al. · Journal of Diabetes and its Complications · 40
Telmisartan inhibits cytokine-induced nuclear factor-κB activation independently of the peroxisome proliferator-activated receptor-γ
2009 · Ayuko Nakano, Yoshiyuki Hattori, et al. · Hypertension Research · 37
PDF
Glimepiride upregulates eNOS activity and inhibits cytokine‐induced NF‐κB activation through a phosphoinoside 3‐kinase–Akt‐dependent pathway
2008 · T. Jojima, K. Suzuki, et al. · Diabetes Obesity and Metabolism · 35
Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells
2010 · Chie Aoki, Ayuko Nakano, et al. · International Journal of Cardiology · 34
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes
2015 · Yoshimasa Aso, T. Jojima, et al. · Endocrine · 33
Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report
2020 · Teruo Jojima, Takahiko Kogai, et al. · European Journal of Endocrinology · 31
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol
2021 · Teruo Jojima, Shintaro Sakurai, et al. · International Journal of Cardiology · 29
Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells
2007 · Hiroyuki Kase, Yoshiyuki Hattori, et al. · Life Sciences · 28
The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes
2013 · Yoshimasa Aso, Tomoko Terasawa, et al. · Translational research · 26
Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients
2011 · Yoshiaki Kawagoe, Yoshiyuki Hattori, et al. · Endocrine Journal · 26
PDF
Time-restricted feeding prevents high-fat and high-cholesterol diet-induced obesity but fails to ameliorate atherosclerosis in apolipoprotein E-knockout mice
2020 · Ken-ichi Inoue, Shigeru Toyoda, et al. · EXPERIMENTAL ANIMALS · 24
PDF
Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells
2017 · Toshie Iijima, Kanako Kato, et al. · Diabetes Research and Clinical Practice · 18
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
2023 · Sho Wakamatsu, Teruo Jojima, et al. · Journal of Diabetes and its Complications · 14
Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease
2021 · Yoshimasa Aso, Masaaki Sagara, et al. · Journal of Investigative Medicine · 14
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis
2021 · Masaaki Sagara, Toshie Iijima, et al. · Journal of Diabetes and its Complications · 13
Works count: 71
Citation count: 1,948
H-index: 21
I10-index: 29
Year
Topic
Type